Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CoTec Holdings Corp T.CTH


Primary Symbol: V.CTH Alternate Symbol(s):  CTHCF

CoTec Holdings Corp. is a Canada-based environment, social, and governance (ESG)- focused company. It is investing in technologies which have the potential to fundamentally change the way metals and minerals can be extracted and processed for the purpose of applying those technologies to undervalued operating assets and recycling opportunities, as it transitions into a mid-tier mineral resource producer. Its assets and technologies are focused on three operating groups: critical minerals, green iron and copper. Its technologies include HyProMag Ltd., Binding Solutions Ltd. (BSL), Ceibo and MagIron. Its assets include HyProMag USA Project, Lac Jeannine Project and MagIron. The HyProMag technology is a patented hydrogen process to extract rare earths from recycled magnets, using 88% less energy with key demagnetization of NdFeB. BSL's technology converts the fine materials from mines/waste dumps into ISO-compliant pellets or briquettes ready for furnace usage to produce green steel.


TSXV:CTH - Post by User

Comment by riverrowon Mar 28, 2014 6:12pm
169 Views
Post# 22384234

RE:RE:what's going on?

RE:RE:what's going on?
Great Call.

2014-03-28 16:58 ET - News Release

 

Mr. Anthony Giovinazzo reports

CYNAPSUS THERAPEUTICS FILES PRELIMINARY SHORT FORM PROSPECTUS

Cynapsus Therapeutics Inc. has filed a preliminary short-form prospectus with the securities regulatory authorities in the provinces of British Columbia, Alberta and Ontario, in connection with a best-efforts offering of common shares and warrants of Cynapsus for gross proceeds of $15-million to $25-million. Final pricing and determination of the number of common shares and warrants to be sold pursuant to the offering will occur immediately prior to the filing of the final short-form prospectus in respect of the offering.

The company has retained M Partners Inc. to lead the offering. An agency agreement for the offering will be entered into by the company and the agent.

Closing of the offering is subject to final pricing and TSX Venture Exchange approval. The net proceeds of the offering will be used to finance research and development activities for the company's APL-130277 Parkinson's disease drug candidate, and for general working capital purposes. The first closing of the offering is expected to occur on or about April 18, 2014

<< Previous
Bullboard Posts
Next >>